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Abstract: Due to the widespread use of ultrasound, small thyroid nodules (TNs) ≤ 10 mm are
common findings. Standardized approaches for the risk stratification of TNs with Thyroid Imaging
Reporting and Data Systems (TIRADS) were evaluated for the clinical routine. With TIRADS, the risk
of malignancy in TNs is calculated by scoring the number or combination of suspicious ultrasound
features, leading to recommendations for further diagnostic steps. However, there are only scarce
data on the performance of TIRADS for small TNs. The aim was to compare three different TIRADS
for risk stratification of small TNs in routine clinical practice. We conducted a retrospective cohort
analysis of TNs ≤ 10 mm and their available histology. Nodules were classified according to three
different TIRADS. In the study, 140 patients (n = 113 female) with 145 thyroid nodules (n = 76
malignant) were included. Most of the malignant nodules were papillary carcinoma (97%), and the
remaining 3% were medullary carcinoma. For all tested TIRADS, the prevalence of malignancy rose
with increasing category levels. The highest negative predictive value was found for ACR TI-RADS
and the highest positive predictive value for Kwak-TIRADS. All tested variants of TIRADS showed
comparable diagnostic performance for the risk stratification of small TNs. TIRADS seems to be a
promising tool to reliably assess the risk of malignancy of small TNs.
Keywords: TIRADS; small thyroid nodules; thyroid carcinomas; risk stratification
1. Introduction
Due to the widespread use of ultrasound as well as the increasing number of imaging studies
performed for reasons other than planned assessment of the thyroid gland (i.e., computed tomography
of the chest or cervical spine, magnetic resonance imaging of the cervical spine, and whole-body
positron emission tomography), incidental thyroid nodules (TNs) ≤ 10 mm are now common
findings [1–5]. The characterization of TNs has improved because of better ultrasound image resolution
and the introduction of new diagnostic ultrasound tools such as elastography [6]. Furthermore,
standardized approaches for the risk assessment of TNs, so-called Thyroid Imaging Reporting and
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Data Systems (TIRADS), have been evaluated for routine clinical use. With TIRADS, the risk of a
malignant TN is calculated by scoring the number or the combination of various suspicious ultrasound
criteria [7–9]. Recently, a number of standardized reporting systems (e.g., ACR TI-RADS, EU-TIRADS,
Korean-TIRADS) have been proposed. These reporting systems also include recommendations
for the appropriate further diagnostic steps [7–9]. For instance, the ACR TI-RADS recommends a
fine-needle-aspiration biopsy (FNA) for highly suspicious TNs if the diameter is 10 mm or larger.
Otherwise, the ACR is in concordance with other guidelines, which do not generally recommend
FNA for the evaluation of nodules smaller than 10 mm [9,10]. The EU-TIRADS, published in
2017, recommends shared decision-making (FNA vs. active surveillance) with the patient when
subcentimetric TNs with highly suspicious ultrasound features without abnormal lymph nodes are
detected [8]. However, there are only scarce data on the performance of TIRADS for small TNs up to
a diameter of 10 mm. The purpose of this study was to compare three different variants of TIRADS
(Kwak-, ACR, and EU-TIRADS) in terms of the risk stratification of small TNs (≤10 mm) in the routine
clinical practice.
2. Experimental Section
This monocentric cohort analysis was approved by the local ethical committee (Magdeburg
University Hospital, No. 43/19) and the need for a written informed consent was waived. Data
collection with standardized thyroid ultrasound started in 2015 for all consecutive patients referred to
our outpatient practice for the assessment of TNs found at neck ultrasound or other imaging modalities,
or suspected thyroid dysfunction. Inclusion criteria for this cohort analysis were the presence of thyroid
nodules ≤ 10 mm measured in B-mode ultrasound (independent of the histopathological size of the
nodule), Kwak-TIRADS classification of the thyroid nodule during ultrasound investigation between
2015 and 2017, and available histopathological results after surgery. Only the categorization of the TNs
according to ACR TI-RADS and EU-TIRADS was performed retrospectively using the (electronically)
archived ultrasound images. We did not include incidental thyroid cancers detected at final histology
and TNs > 10 mm measured with ultrasound. The malignant TNs were histopathologically classified
according to the 8th UICC edition of TNM classification and modified according to Schmid et al.
2018, where pT1a2 carcinomas replaces pT3 ≤ 10 mm with minimal extrathyroidal extension [11,12].
According to the German guidelines, thyroid scans (data not shown) were performed only if one
or more nodules had a diameter of ≥ 10 mm or in patients with a low TSH level [13]. Due to the
retrospective design of this cohort study, there were various reasons for thyroid surgery, such as to
exclude the malignancy of TNs with suspicious findings on ultrasound, FNA, or 99mTc-MIBI imaging;
thyroid nodules accompanied by suspicious cervical lymph nodes or growth during follow-up; the
patient’s wish for a definite histopathological diagnosis; or local symptoms related to the thyroid.
Thyroid ultrasound was performed by three qualified investigators with two to five years of
experience in Kwak-TIRADS classification and more than 7 years each in thyroid ultrasound using
B-mode ultrasound with a linear probe with a frequency of 8–13 MHz (HITACHI Avius Hi Vision,
Chiyoda, Japan). For all nodules, the composition (completely solid, almost completely solid, 10–50%
cystic changes, >50% cystic proportion), echogenicity (hypoechogenicity, marked hypoechogenicity,
isoechogenicity, hyperechogenicity), margins (well circumscribed, irregular, spiculated), presence
of internal calcification (hyperechoic spots, microcalcifications, macrocalcifications, none), and the
orientation of the nodule (taller-than-wide, wider-than-tall) was documented. Additionally, the size of
each nodule was assessed.
Kwak-TIRADS calculates a score as the sum of ultrasound characteristics that are present in the
TNs of interest. The number of suspicious ultrasound features (e.g., solid or almost solid nodule,
hypoechogenicity, irregular margins, presence of microcalcifications, and a taller than wide shape,
respectively) are used to reveal a score of TIRADS 3, 4A, 4B, 4C, or 5. As the number of suspicious
features increases, so does the risk of malignancy [7]:
TIRADS 3: no suspicious features (risk 1.7%);
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TIRADS 4A: one suspicious feature (risk 3.3%);
TIRADS 4B: two suspicious features (risk 9.2%);
TIRADS 4C: three or four suspicious features (risk 44.4–72.4%);
TIRADS 5: five suspicious features (risk 87.5%).
EU-TIRADS defines four ultrasound features of high suspicion for malignancy (non-oval or round
shape, irregular margins, microcalcifications, and a marked hypoechogenicity) [8]:
EU-TIRADS 2: anechoic or entirely spongiform (benign, risk 0%);
EU-TIRADS 3: entirely isoechoic or hyperechoic (low risk, risk 2–4%);
EU-TIRADS 4: mildly hypoechoic (intermediate risk, risk 6–17%);
EU-TIRADS 5: at least one of the four features of high suspicion (high risk, risk 26–87%).
ACR TI-RADS is a more sophisticated scoring system with five ultrasound features (composition,
echogenicity, shape, margin, and echogenic foci). Each feature is described in detail and weighted by
allocating points to create a summed score [9]:
TR1: 0 points, benign (aggregate risk level 0.3%);
TR2: 2 points, not suspicious (aggregate risk level 1.5%);
TR3: 3 points, mildly suspicious (aggregate risk level 4.8%);
TR4: 4–6 points, moderately suspicious (aggregate risk level 5.9–12.8%);
TR5: 7 points or more, highly suspicious (aggregate risk level 20.8–68.4% for 10 points).
In our study we defined the cutoffs as suspicious for malignancy for Kwak-TIRADS ≥ 4C,
EU-TIRADS > 4, and ACR TI-RADS ≥ 4, respectively.
2.1. Pathological Examination
The tissue samples were fixed in 4% formaldehyde solution. After dehydration they were
embedded in paraffin. Slices with a thickness of 5 µm were stained using hematoxylin-eosin. In the
case of follicular neoplasia, additional cuts were performed and EvG (Elastica van Gieson stain) was
applied. Microscopic assessment of the slices was performed in 20-fold to 400-fold enlargements.
2.2. Statistics
All statistical tests were performed using WinSTAT for Microsoft® Excel version 2005.1. The results
were expressed as mean, standard deviation (SD), median, and 25th/75th percentile, respectively.
The variables were tested using the t-test and the Mann–Whitney test as indicated. Adjusting for
multiple comparisons using Bonferroni correction, results were considered to be significant if a p-value
of <0.01 was found.
3. Results
We included 140 patients (n = 113 female (81%) with a mean age of 46.3 ± 11.4 years and
n = 27 male with a mean age of 58.2 ± 12.6 years) with 145 TNs (n = 76 malignant nodules (52%),
mean size 7.6 ± 1.9 mm and n = 69 benign nodules, mean size 7.8 ± 1.8 mm, p = 0.608). Most of
the malignant nodules were papillary thyroid carcinomas (PTC, 97%), and the remaining 3% were
medullary carcinomas (MTC). Of the carcinomas, 55 (72%) were pT1a1 tumors and 9 (12%) were
pT1a2 tumors. Twelve malignant nodules (16%) were classified as pT1b tumors in final histopathology
because the histopathological size was larger than the size measured by sonography (n = 12/76, 15.7%).
Lymph node metastases (LNMs) were found in 20% of the PTC and there were no LNMs in the two
cases of MTC (Table 1). Histopathology revealed multifocality in 39% of the PTCs. Malignant nodules
were significantly more often solitary nodules than benign nodules (p < 0.001).
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Table 1. Thyroid carcinomas (TC) and lymph node metastases stages.
All TC n = 76 TC pT1a1 n = 55 TC pT1a2 n = 9 TC pT1b n = 12
pN0 n (%) 37 (48.7) 26 (47.2) 4 (44.5) 7 (58.3)
pN1 n (%) 15 (19.7) 9 (16.4) 3 (33.3) 3 (25.0)
pNX n (%) 24 (31.6) 20 (36.4) 2 (22.2) 2 (16.7)
For all examined variants of TIRADS, with increasing TIRADS category the prevalence of
malignancy also increased. The prevalence of malignancy for Kwak-TIRADS classes 3, 4A, 4B, 4C,
and 5 was 0%, 0%, 16.7%, 67.9%, and 81%, respectively. In EU-TIRADS for classes 2–5 the malignancy
rate was 0%, 4.2%, 8.3%, and 67.9%, whereas the prevalence of malignancy for ACR TI-RADS classes
TR1–TR5 was 0%, 0%, 0%, 56.1%, and 69.7%, respectively (Table 2).
Table 2. Distribution of malignant and benign thyroid nodules for all tested variants of Thyroid
Imaging Reporting and Data Systems (TIRADS) classifications.
Malignant Thyroid
Nodules (n = 76, %)
Benign Thyroid Nodules
(n = 69, %)
Prevalence of
Malignancy (%)
Kwak-TIRADS
3 n (%) 0 (0) 9 (13.1) 0
4A n (%) 0 (0) 19 (27.5) 0
4B n (%) 2 (2.6) 10 (14.5) 16.7
4C n (%) 57 (75.0) 27 (39.1) 67.9
5 n (%) 17 (22.3) 4 (5.8) 81.0
ACR TI-RADS
TR1 n (%) 0 (0) 4 (5.8) 0
TR2 n (%) 0 (0) 8 (11.6) 0
TR3 n (%) 0 (0) 16 (23.2) 0
TR4 n (%) 23 (30.3) 18 (26.1) 56.1
TR5 n (%) 53 (69.7) 23 (33.3) 69.7
EU-TIRADS 0 (0)
2 n (%) 0(0) 0 (0) 0
3 n (%) 1 (1.3) 23 (33.3) 4.2
4 n (%) 1 (1.3) 11 (15.9) 8.3
5 n (%) 74 (97.4) 35 (50.7) 67.9
All of the malignant nodules were solid or almost completely solid (benign TNs: 73%). The
malignant nodules were hypoechoic (95%), the margins were more often irregular (92%), and they
showed more microcalcifications (62%) compared to the benign ones (67% hypoechoic, 36% irregular
margins, and 32% microcalcifications). All suspicious features documented at thyroid ultrasound were
significantly more frequent in malignant nodules than in benign nodules (Figure 1). The diagnostic
performance values of TIRADS are listed in Table 3. The highest negative predictive value to rule out
malignancy was found for ACR TI-RADS. The positive predictive value was comparable for all tested
variants of TIRADS; all systems showed low specificity (Table 3).
Table 3. Diagnostic performance of Kwak-TIRADS, EU-TIRADS, and ACR TI-RADS.
Sensitivity (%) Specificity (%)
Positive
Predictive
Value (%)
Negative
Predictive
Value (%)
Accuracy (%)
Kwak-TIRADS
4C and 5 97.4 55.1 70.5 95 77.2
ACR-TI-RADS
TR4 and TR5 100 40.6 65 100 71.7
EU-TIRADS 5 97.4 49.3 67.9 94.4 74.5
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size group [21]. Our results are also supported by a recent study by Ha et al. [22]. The authors 
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as described in a meta-analysis by Castellana t al. [19]. However, data are rare regarding the diagnostic
performance of TIRADS concer ing TNs with a maximum size of 10 mm. This study compare the
three most commonly used TIRADS in small TNs. Our study d monstrates that 97% of the malignant
TNs presen d with a high-risk Kwak-TIRADS (4C or 5) or EU-TIRADS (EU 5) classification and
that 100% presented with an ACR TI-RADS TR4 or 5. Th se high sensitivities are comparable to the
results of Du et al., where the Kwak-TIRADS alone and in combination with ultrasound elastography
was tested i small TNs [20]. However, contrary to our study they summarized Kwak-TIRADS
4B–5 as malignant, because the prevalence of alig a cy for Kwak-TIRADS 4B was remarkably
high: 70.5% vs. 16.7% in our study and 9.2 in the data from the original paper of Kwak et al.
The accuracy for K ak-TIRADS alone was found to be 83.8%, slightly higher than our results for
Kwak-TIRADS. This major discrepancy in TIRADS 4B accuracy might be caused by a center-specific
selection bias. Considering the distribution of the ultrasound features, Du et al. described that most
of the malignant TNs were solid, hypoechoic, and showed irregular margins, comparable to our
results. However, we found a lower percentage of malignant TNs with a taller-than-wide shape
than Du et al. (45% versus 58%) and a higher percentage of microcalcifications in malignant TNs
(61% versus 44%). Another study by Mendes et al. examined whether Kwak-TIRADS is useful for
the assessment of subcentimetric TNs. The nodules were divided into two groups (2–5 mm and
6–10 mm, respectively). In accordance with our results, they demonstrated that the rate of malignancy
increased with the number of suspicious features, independent of the nodule size group [21]. Our
results are also supported by a recent study by Ha et al. [22]. The authors evaluated the performance
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of different TIRADS (Korean-TIRADS, French-TIRADS, ATA scoring system, and a web-based system
among others) in TNs smaller than 10 mm. The authors focused on the low malignancy rates of
“low-suspicion” TIRADS classes. These results indicate that the use of TIRADS could prevent the
overdiagnosis and overtreatment of “low-risk” TNs [22]. In our study, the rate of malignancy in the
“low-risk” TIRADS classes (Kwak-TIRADS 3 and 4A, ACR TI-RADS TR1 and TR2, and EU-TIRADS
EU 2 and 3, respectively) was 0% for Kwak-TIRADS and ACR TI-RADS, and 1.3% in EU-TIRADS.
However, the proportion of nodules classified as “low-risk” was very small (Kwak-TIRADS 19%, ACR
TI-RADS 8%, and EU-TIRADS 17%). This finding is likely caused by a selection bias in our study, which
leads to a small number of cases with low TIRADS classes that were referred to thyroid surgery or FNA.
In another study, Weiss et al. focused on the use of ACR TI-RADS for 61 subcentimetric TNs. As the
gold standard, the results of FNA (Bethesda system) were used. Of five papillary carcinomas, all were
classified as TR4/TR5 (“high-risk” nodules). Comparable to our results, of the nodules that presented
with a low TIRADS score (TR1/TR2), 88% were benign on FNA (12% were nondiagnostic/unsatisfactory,
none of them were malignant in Bethesda classification). They concluded that TIRADS may also be
used for risk stratification of small TNs and that lesions with a low TIRADS score may be followed
without the need for immediate FNA [23]. Interestingly, we underestimated the size of 16% of the PTC
with B-mode sonography. These results are in concordance with other studies. Zhao et al. found rates
of underestimation for TNs ≤ 10 mm of 8.3%, whereas Deveci et al. described rates of 14.3% [24,25].
In the study of Hahn et al. the tumor size agreement between sonographical and histopathological
measurements was defined as a difference of less than 20% and they found a rate of underestimation of
13.2%. They stated that ultrasound size measurement is influenced by cystic changes and irregular
margins of the nodules [26].
Limitations
This study has several limitations. First, this study is a retrospective analysis and a selection bias
is unavoidable. We started using TIRADS in daily routine in our outpatient practice and referral center
in 2015. With increasing experience and continued use there was a shift of indication for surgery from
“multinodular goiter with nodules” to “suspicious thyroid nodule”. A shared decision-making process
together with the patients was introduced, especially for younger patients who asked for a definitive
exclusion of malignancy by histopathology. Moreover, the small number of nodules in the “low-risk”
classes as well as the very high percentage of malignant TNs in our cohort can be explained by this
selection bias and the fact that nodules that appeared benign in the ultrasonographic examination
were not referred to further diagnostic workup by FNA or surgery. Additionally, this selection bias
may affect the negative and positive predicting value. Therefore, prospective studies with a more
balanced distribution are desirable. Secondly, we also did not evaluate the interobserver variability of
the different reporting systems in this study. In order to minimize the variability in the assessment
of the sonographic features, image data were routinely reviewed by all participating physicians and
TIRADS consensus building was established. Furthermore, we conducted a multicenter study to
compare the interobserver variability of different imaging reporting systems (data not shown) [27].
Thirdly, the classifications according to ACR TI-RADS and EU-TIRADS were performed only by one
experienced physician by reviewing the archived ultrasound images that were partly recorded by a
different examiner. Thus, it cannot be excluded that not all relevant sonographic criteria were stored,
particularly at the beginning of the standardized ultrasonography in 2015. Fourthly, most of the
malignant nodules were papillary thyroid carcinomas. Therefore, the diagnostic performance in other
types of thyroid cancer requires further investigation.
5. Conclusions
In our study, ACR TI-RADS with a cutoff ≥ TR4 showed the highest sensitivity and negative
predictive value, whereas a Kwak-TIRADS score ≥ 4C had the highest positive predictive value and
accuracy. TIRADS seems to be a promising clinical tool to reliably assess the risk of malignancy of small
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thyroid nodules, even in primary care settings, and to select thyroid nodules for further diagnostic
workup. Furthermore, it might be considered to extend the follow-up time for small thyroid nodules
and low-risk TIRADS classification.
Author Contributions: Conceptualization and methodology, S.S., M.Z., R.G. and P.S. (German TIRADS Study
Group); writing—original draft preparation, S.S., M.Z.; writing—review and editing, M.C.K., R.G., R.K., S.S., M.Z.;
statistics, P.S., S.S.; supervision and language editing, M.C.K. All authors have read and agreed to the published
version of the manuscript.
Conflicts of Interest: All authors declare that they have no conflicts of interest.
References
1. Grady, A.T.; Sosa, J.A.; Tanpitukpongse, T.P.; Choudhury, K.R.; Gupta, R.T.; Hoang, J.K. Radiology reports for
incidental thyroid nodules on CT and MRI: High variability across subspecialties. AJNR Am. J. Neuroradiol.
2015, 36, 397–402. [CrossRef]
2. Farra, J.C.; Picado, O.; Liu, S.; Ouyang, W.; Teo, R.; Franco, A.M.; Lew, J.I. Clinically significant cancer rates
in incidentally discovered thyroid nodules by routine imaging. J. Surg. Res. 2017, 219, 341–346. [CrossRef]
3. Li, Y.; Cui, M.; Azar, N.; Nakamoto, D.; Michael, C.W. Cytological evaluation by fine needle aspiration biopsy
of incidental focal increased fluorodeoxyglucose uptake in thyroid on positron emission tomography scan.
Diagn. Cytopathol. 2017, 45, 501–506. [CrossRef] [PubMed]
4. Park, J.Y.; Lee, K.H.; Cho, S.G.; Kim, Y.J.; Lee, H.Y.; Hong, I.K.; Kim, J.H. Incidental thyroid nodules on thoracic
contrast-enhanced computed tomography in clinical practice during a 10-year period: Characteristics, clinical
outcomes, and factors contributing to further evaluation. Medicine 2017, 96, e6388. [CrossRef] [PubMed]
5. Fisher, S.B.; Perrier, N.D. The incidental thyroid nodule. CA Cancer J. Clin. 2018, 68, 97–105. [CrossRef]
[PubMed]
6. Tian, W.; Hao, S.; Gao, B.; Jiang, Y.; Zhang, X.; Zhang, S.; Guo, L.; Yan, J.; Luo, D. Comparing the diagnostic
accuracy of RTE and SWE in differentiating malignant thyroid nodules from benign ones: A meta-analysis.
Cell. Physiol. Biochem. 2019, 39, 2451–2463. [CrossRef]
7. Kwak, J.Y.; Han, K.H.; Yoon, J.H.; Moon, H.J.; Son, E.J.; Park, S.H.; Jung, H.K.; Choi, J.S.; Kim, B.M.; Kim, E.K.
Thyroid imaging reporting and data system for US features of nodules: A step in establishing better
stratification of cancer risk. Radiology 2011, 260, 892–899. [CrossRef]
8. Russ, G.; Bonnema, S.J.; Erdogan, M.F.; Durante, C.; Ngu, R.; Leenhardt, L. European Thyroid Association
guidelines for ultrasound malignancy risk stratification of thyroid nodules in adults: The EU-TIRADS. Eur.
Thyroid J. 2017, 6, 225–237. [CrossRef]
9. Tessler, F.N.; Middleton, W.D.; Grant, E.G.; Hoang, J.K.; Berland, L.L.; Teefey, S.A.; Cronan, J.J.; Beland, M.D.;
Desser, T.S.; Frates, M.C.; et al. ACR thyroid imaging, reporting and data system (TI-RADS): White paper of
the ACR TI-RADS committee. J. Am. Coll. Radiol. 2017, 14, 587–595. [CrossRef]
10. Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.;
Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association management
guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid
Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016, 26,
1–133. [CrossRef]
11. Schmid, K.W.; Synoracki, S.; Dralle, H.; Wittekind, C. Proposal for an extended pTNM classification of
thyroid carcinoma: Commentary on deficits of the 8th edition of the TNM classification. Pathologe 2018.
[CrossRef] [PubMed]
12. Sobin, L.H.; Gospodarowicz, M.K.; Wittekind, C. TNM Classification of Malignant Tumours, 7th ed.;
Wiley-Blackwell: Hoboken, NJ, USA, 2009; pp. 58–62.
13. Dietlein, M.; Eschner, W.; Lassmann, M.; Verburg, F.; Luster, M. Procedure Guideline for Thyroid Scintigraphy
(Version 4). 2014. Available online: http://www.nuklearmedizin.de/leistungen/leitlinien/docs/031011l_S1_
Schilddruesenszintigraphie_2014-10.pdf (accessed on 2 December 2019).
14. Leboulleux, S.; Tuttle, R.M.; Pacini, F.; Schlumberger, M. Papillary thyroid microcarcinoma: Time to shift
from surgery to active surveillance? Lancet Diabetes Endocrinol. 2016, 4, 933–942. [CrossRef]
15. Miyauchi, A. Clinical trials of active surveillance of papillary microcarcinoma of the thyroid. World J. Surg.
2016, 40, 516–522. [CrossRef] [PubMed]
J. Clin. Med. 2020, 9, 236 8 of 8
16. Miyauchi, A.; Ito, Y.; Oda, H. Insights into the management of papillary microcarcinoma of the thyroid.
Thyroid 2018, 28, 23–31. [CrossRef] [PubMed]
17. Oda, H.; Miyauchi, A.; Ito, Y.; Sasai, H.; Masuoka, H.; Yabuta, T.; Fukushima, M.; Higashiyama, T.; Kihara, M.;
Kobayashi, K.; et al. Comparison of the costs of active surveillance and immediate surgery in the management
of low-risk papillary microcarcinoma of the thyroid. Endocr. J. 2017, 64, 59–64. [CrossRef] [PubMed]
18. Horvath, E.; Majlis, S.; Rossi, R.; Franco, C.; Niedmann, J.P.; Castro, A.; Dominquez, M. An ultrasound
reporting system for thyroid nodules stratifying cancer risk for clinical management. J. Clin. Endocrinol.
Metab. 2009, 94, 1748–1751. [CrossRef] [PubMed]
19. Castellana, M.; Castellana, C.; Treglia, G.; Giorgino, F.; Giovanella, L.; Russ, G.; Trimboli, P. Performance of
five ultrasound risk stratification systems in selecting thyroid nodules for FNA. A meta-analysis. J. Clin.
Endocrinol. Metab. 2019. [CrossRef]
20. Du, Y.R.; Ji, C.L.; Wu, Y.; Gu, X.G. Combination of ultrasound elastography with TI-RADS in the diagnosis of
small thyroid nodules (≤10 mm): A new method to increase the diagnostic performance. Eur. J. Radiol. 2018,
109, 33–40. [CrossRef]
21. Mendes, G.F.; Garcia, M.R.; Falsarella, P.M.; Rahal, A.; Cavalcante Junior, F.A.; Nery, D.R.; Garcia, R.G. Fine
needle aspiration biopsy of thyroid nodule smaller than 1.0 cm: Accuracy of TIRADS classification system in
more than 1000 nodules. Br. J. Radiol. 2018, 91, 20170642. [CrossRef]
22. Ha, S.M.; Kim, J.K.; Baek, J.H. Detection of malignancy among suspicious thyroid nodules ≤1cm on
ultrasound with various thyroid image reporting and data systems. Thyroid 2017, 27, 1307–1315. [CrossRef]
23. Weiss, V.L.; Andreotti, R.F.; Ely, K.A. Use of thyroid imaging, reporting, and data system (TI-RADS) scoring
system for the evalution of subcentimeter thyroid nodules. Cancer Cytopathol. 2018, 126, 518–524. [CrossRef]
[PubMed]
24. Deveci, M.S.; Deveci, G.; LiVolsi, V.A.; Gupta, P.K.; Baloch, Z.W. Concordance between thyroid nodule size
measured by ultrasound and gross pathology examination: Effect on patient management. Diagn. Cytopathol.
2007, 35, 579–583. [CrossRef] [PubMed]
25. Zhao, L.; Yan, H.; Pang, P.; Fan, X.; Jia, X.; Zang, L.; Luo, Y.; Wang, F.; Yang, G.; Gu, W.; et al. Thyroid nodule
size calculated using ultrasound and gross pathology as predictors of cancer: A 23-year retrospective study.
Diagn. Cytopathol. 2019, 47, 187–193. [CrossRef] [PubMed]
26. Hahn, S.Y.; Shin, J.H.; Oh, Y.L.; Son, Y.I. Discrepancies between the ultrasonographic and gross pathological
size of papillary thyroid carcinomas. Ultrasonography 2016, 36, 220–225. [CrossRef] [PubMed]
27. Seifert, P.; Görges, R.; Zimny, M.; Kreissl, M.C.; Schenke, S. Interobserver agreement and efficacy of consensus
reading in Kwak-, EU-, and ACR thyroid imaging recording and data systems and ATA guidelines for the
ultrasound risk stratification of thyroid nodules. Endocrine 2019. accepted. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
